Nuvalent, Inc. financial data

Symbol
NUVL on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.08K % +0.73%
Debt-to-equity 6.03 % +19.9%
Return On Equity -29.8 % -15.7%
Return On Assets -28.1 % -14.6%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 2.6B USD +136%
Weighted Average Number of Shares Outstanding, Basic 66.4M shares +14.1%
Weighted Average Number of Shares Outstanding, Diluted 66.4M shares +14.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 218M USD +92.3%
General and Administrative Expense 62.6M USD +72.7%
Operating Income (Loss) -280M USD -87.5%
Nonoperating Income (Expense) 20.4M USD -12.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -260M USD -106%
Income Tax Expense (Benefit) 764K USD
Net Income (Loss) Attributable to Parent -261M USD -107%
Earnings Per Share, Basic -3.93 USD/shares -81.1%
Earnings Per Share, Diluted -3.93 USD/shares -81.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 146M USD -56.6%
Marketable Securities, Current 973M USD +153%
Assets, Current 1.13B USD +55.9%
Other Assets, Noncurrent 9.3M USD +57.8%
Assets 1.14B USD +55.9%
Accounts Payable, Current 5.23M USD -43.7%
Employee-related Liabilities, Current 10.5M USD +42.7%
Accrued Liabilities, Current 48.8M USD +116%
Liabilities, Current 54M USD +69.8%
Liabilities 72M USD +126%
Accumulated Other Comprehensive Income (Loss), Net of Tax -59K USD -290%
Retained Earnings (Accumulated Deficit) -547M USD -91.1%
Stockholders' Equity Attributable to Parent 1.07B USD +52.7%
Liabilities and Equity 1.14B USD +55.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -36.1M USD -47.8%
Net Cash Provided by (Used in) Financing Activities 5.99M USD
Net Cash Provided by (Used in) Investing Activities -207M USD -62.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -237M USD -56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146M USD -56.6%
Deferred Tax Assets, Valuation Allowance 220M USD +118%
Deferred Tax Assets, Gross 220M USD +118%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -261M USD -108%
Deferred Tax Assets, Operating Loss Carryforwards 56.7M USD +61.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 60.6M USD +137%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%